Bausch + Lomb Corp has seen a slight uptick in its stock price this week, with recent developments in eye health therapies driving investor interest.
Bausch + Lomb Corp (BLCO.TO) has experienced a modest increase in its stock price, closing at C$23.99, marking a 1.40% rise over the past week and a 7.02% increase over the last month. The healthcare company is currently in the spotlight due to advancements in its product pipeline, particularly in eye health therapies.
Investor takeaway: Investors may want to keep an eye on Bausch + Lomb's progress in clinical trials and product development, as these factors could influence market sentiment and stock performance moving forward.
Advertisement
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.54B
52W high
$25.70
52W low
$19.36
1W change
+2.13%
Beta
0.55
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to rise 3.8% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$24.91
+3.8% Upside
Current Price
C$23.99
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
26.4%
Annualized
90-Day Vol
27.8%
Annualized
Trend (90d)
+45.0%
Annualized drift
90d Mean
C$28.18
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$25.31 | C$23.11 โ C$27.72 |
| 60 trading days | C$26.71 | C$23.48 โ C$30.37 |
| 90 trading days | C$28.18 | C$24.07 โ C$32.99 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bausch + Lomb's Stock Ranges from C$19.36 to C$25.70 Over the Past Year
Currently, the stock is trading at 73% of its 52-week range, indicating potential room for growth but also highlighting volatility in its price movements.
Bull case
Bausch + Lomb's advancements in dual-action eye drops and first-in-class therapies could give it a competitive edge in the eye care market. This progress may lead to increased revenue and boost investor confidence.
Bear case
Despite recent gains, the company's negative profit margins and return on equity may raise concerns among investors about its financial health and long-term sustainability.
Recent Price Action
Bausch + Lomb Corp's stock closed at C$23.99, reflecting a 0.46% increase for the day and a 1.40% rise over the past week. The stock has shown solid performance with a 7.02% increase over the last month and a year-to-date gain of 4.96%. The trading volume for the latest session was 901 shares, which is only 50% of the 20-day average volume of 1,818 shares.
Advertisement
Company News and Catalysts
Recent headlines surrounding Bausch + Lomb include significant progress in their clinical trials. On August 24, the company announced plans to advance a dual-action eye drop designed to target both evaporative and inflammatory dry eye disease to Phase 3 trials. Additionally, they are moving forward with two first-in-class eye health therapies based on recent trial results. These developments have sparked interest among investors, as they may enhance the company's product offerings and market position.
Technical Picture
From a technical standpoint, Bausch + Lomb's stock is currently trading above both its 50-day moving average (C$22.89) and its 200-day moving average (C$22.76), indicating a bullish trend in the short to medium term. The stock's 52-week range of C$19.36 to C$25.70 shows it is currently at 73% of its range, suggesting potential for further upward movement. The stock has a beta of 0.55, indicating lower volatility compared to the broader market.
Insider Activity
No significant insider activity has been reported recently, which may suggest stability in the management's commitment to the company's future direction.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
